Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Hierarchical interplay between H3K27ac and H3K4me3 in transcriptional regulation.

Nature communications·2026

Same author

Hierarchical Interplay between H3K27ac and H3K4me3 in Transcriptional Regulation.

bioRxiv : the preprint server for biology·2026

Same author

ZNF184 negatively regulates HR repair and predicts poor prognosis in acute lymphoblastic leukemia.

Nucleic acids research·2026

Same author

Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma.

BMC medicine·2026

Same author

Cyclic γ-AApeptide-Based Molecular Glues for RNA m<sup>6</sup>A Editing.

ACS chemical biology·2026

Same author

Leveraging cell's endogenous regulatory network: towards safer and more effective CAR T cell therapies for solid tumors.

Translational cancer research·2026

Search research articles

相关实验视频

Updated: May 16, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

工程TME-gate诱导性CAR-T细胞疗法用于固体瘤.

Huong T X Nguyen¹, Byung-Gyu Kim², Jay T Myers³

¹Department of Chemistry, Case Western Reserve University (CWRU), Cleveland, OH, USA; Case Comprehensive Cancer Center, CWRU School of Medicine, Cleveland, OH, USA.

Molecular therapy : the journal of the American Society of Gene Therapy

|May 1, 2025

概括

此摘要是机器生成的。

下一代CAR-T细胞,TME-iCAR-T,使用遗传 AND 门来感知多个瘤信号. 这增强了癌细胞的向性,并减少了毒性,以获得更安全的免疫疗法.

关键词:

在CAR-T细胞中.在CIP中,我们可以使用CIP.癌症信号癌症信号小分子分子小分子固体瘤是一种固体瘤.瘤微环境是一个微环境.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关实验视频

Last Updated: May 16, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

科学领域:

免疫学免疫学免疫学
生物技术是生物技术.
癌症治疗癌症治疗

背景情况:

化学抗原受体 (CAR) -T细胞疗法提供了革命性的癌症治疗.
由于不精确的激活,CAR-T细胞疗法面临着针对性,非瘤毒性的挑战.
需要先进的监管控制系统来提高CAR-T细胞的精度和安全性.

研究的目的:

开发一种具有增强瘤选择性和安全性的新型CAR-T细胞策略.
创建下一代CAR-T细胞,TME-iCAR-T,能够感知多种瘤特异性特征.
整合化学诱导近距离 (CIP) 和瘤激活前药物,以精确调节CAR-T细胞.

主要方法:

设计了一种基因"AND"门系统,集成基于酸 (ABA) 的CIP和基于反应性的/传感技术.
通过将ABA与酸芳香衍生物结合而开发出对缺氧反应的小分子前药物.
利用瘤微环境 (TME) 中的特定癌症信号来激活前药物和控制CAR-T细胞功能.

主要成果:

在实验室中,TME-iCAR-T细胞对结合的瘤信号表现出特定的反应.
实现了癌症信号受限激活和增强了对癌细胞的细胞毒性.
在异种移植前列腺瘤模型中展示了可控性和显著的抗瘤疗效.

结论:

开发的TME-iCAR-T细胞策略为精确向癌细胞提供了一个有希望的方法.
这种模块化的多标准控制系统增强了基于细胞的免疫疗法中的瘤选择性和安全性.
代表了克服CAR-T细胞相关毒性的重大进展,以改善癌症治疗结果.